Rapid Micro reports record Q4 revenue $11.3M (+37% YoY); 2026 guidance $37-41M; Samsung Biologics expands Growth Direct

RAPID MICRO BIOSYSTEMS, INC.

Q4 total revenue $11.3M (+37% YoY); product revenue $9.3M (+78%).
FY 2025 revenue $33.6M (+20% YoY); net loss $47.1M ($1.05/share).
FY 2026 guidance: revenue $37-41M, 30-38 system placements, gross margin ~20%.
Samsung Biologics placed multi-system Growth Direct order in Q1 2026, following Amgen's Q4 2025 multi-system order.
Cash position $39M; $25M unused under Trinity Capital debt facility.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.